Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritus

Trial Profile

An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritus

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serlopitant (Primary)
  • Indications Pruritus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Itch
  • Sponsors Menlo Therapeutics
  • Most Recent Events

    • 31 Oct 2019 According to a Menlo Therapeutics media release, Over 450 patients have been enrolled in this open-label study to date.
    • 06 May 2019 Planned number of patients changed from 400 to 700.
    • 06 May 2019 Planned End Date changed from 1 Sep 2020 to 1 May 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top